What Women Want? The State of the Art regarding the Treatment of Young Women with Hypoactive Sexual Desire Disorder
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 227 KB, PDF-dokument
Keywords:Hypoactive sexual desire disorder, Premenopausal women, Drug treatment, Psychological intervention, Sexual dysfunction
Originalsprog | Engelsk |
---|---|
Tidsskrift | Pharmacology |
Vol/bind | 109 |
Udgave nummer | 2 |
Sider (fra-til) | 69-70 |
Antal sider | 7 |
ISSN | 0031-7012 |
DOI | |
Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:
This review refers to information presented at a conference symposium supported with an unrestricted grant to the European Society for Sexual Medicine by Freya Pharmaceuticals. Leonor de Oliveira, Shelly Varod, and Giovanni Corona have no conflict of interest to declare. Annamaria Giraldi declares the following: Eli Lilly – lecturer, consultant; Boehringer and Pfizer/Viatris – lecturer, advisory board; Palatin Technologies, Sandoz, Emotional Brain, Futura Medical, OvacoBio, and Freya – advisory board; Astellas – lecturer; Novo Nordic – stockholder, lecturer. Linda Vignozzi declares to have received funding from the following companies for scientific research, advisory board attendance, and speaker honoraria: Therascience, Theramex, Bayer-Schering Pharma, Intercept Pharmaceutics, Lipocine Incorporated, Bruno Pharmaceutics, Penta, Ibsa Farmaceutici Italia, Galecto Inc., and Freya. Yacov Reisman declares the following: Freya, Ohhmed, and Viatris – advisory board; Besins Healthcare – advisory board, speaker; Coloplast, Boston Scientific, Berlin-Chemie, and Lundback – speaker.
Publisher Copyright:
© 2023 S. Karger AG. All rights reserved.
ID: 386599459